Causes of transsexuality Docter and others, but opposed by Charles Allen Moser, Larry Nuttbrock, Julia Serano, and the World Professional Association for Transgender Health.<section end="factors" /> A 2008 study compared 112 male-to-female transsexuals (both androphilic and gynephilic), mostly already undergoing hormone treatment, with 258 cisgender male controls. Male-to-female transsexuals were more likely than cisgender males to have a longer version of a receptor gene (longer repetitions of the gene) for the sex hormone androgen or testosterone, which reduced its effectiveness at binding testosterone. The androgen receptor (NR3C4) is activated by the binding of testosterone or dihydrotestosterone, where it plays a critical role in
Transgender hormone therapy about their care, whether they wish to take the NHS or private route without putting their health and indeed their lives in danger." Self-administration of hormone replacement medications may have untoward health effects and risks. Transgender hormone therapy Transgender hormone therapy, also sometimes called cross-sex hormone therapy, is a form of hormone replacement therapy (HRT) in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of HRT is given as one of two types, based on whether